New drug combo aims to Fast-Track UC remission
NCT ID NCT06095596
First seen May 03, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This study tests a new treatment plan for people with moderate to severe ulcerative colitis (UC). It combines two drugs: upadacitinib, which works quickly to reduce symptoms, followed by vedolizumab, which is safer for long-term use. The goal is to see if this sequence can help patients achieve remission faster and maintain it safely. About 334 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
the Sixth Affiliated Hospital of Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 501655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.